Morphometric similarity differences in drug-naive Parkinson's disease correlate with transcriptomic signatures.

These findings advance our understanding of the microscale genetic and cellular mechanisms driving macroscale morphological abnormalities in early drug-naive PD patients and provide potential targets for future therapeutic trials.